eligibility_summary
Eligible: Adults (≥18) with confirmed MS starting ofatumumab for the first time, where initiation was the physician’s independent, routine decision, not opposed to participation, able to complete questionnaires. Exclusion: Prior ofatumumab use within a clinical trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06157086 is an observational, real‑world study in France assessing quality of life in adults with MS who initiate ofatumumab (Kesimpta). Intervention: Ofatumumab, a fully human IgG1 monoclonal antibody (immunotherapy) given in routine care. Mechanism of action: selectively binds CD20 on B lymphocytes and depletes them via complement‑dependent cytotoxicity and antibody‑dependent cellular cytotoxicity (and apoptosis), while sparing stem cells and plasma cells. Target cells/pathways: CD20+ B cells (pre‑B to mature B cells), suppresses B‑cell–mediated antigen presentation, costimulation of T cells, cytokine production, and autoantibody‑related inflammatory pathways relevant to MS.